
EZM 2302
CAS No. 1628830-21-6
EZM 2302 ( GSK 3359088 | GSK3359088 | EZM2302 )
产品货号. M12435 CAS No. 1628830-21-6
EZM 2302 (EZM2302, GSK 3359088) 是一种有效的、选择性的、口服的精氨酸甲基转移酶 CARM1 抑制剂,IC50 为 6 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥1345 | 有现货 |
![]() ![]() |
10MG | ¥2001 | 有现货 |
![]() ![]() |
25MG | ¥3839 | 有现货 |
![]() ![]() |
50MG | ¥5095 | 有现货 |
![]() ![]() |
100MG | ¥7250 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称EZM 2302
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述EZM 2302 (EZM2302, GSK 3359088) 是一种有效的、选择性的、口服的精氨酸甲基转移酶 CARM1 抑制剂,IC50 为 6 nM。
-
产品描述EZM 2302 (EZM2302, GSK 3359088)?is a potent, selective, orally available arginine methyltransferase CARM1 inhibitor with IC50 of 6 nM, with broad selectivity against other HMTases; demonstrates in vitro anti-proliferative activity consistent with specific methyl mark inhibition with IC50 of <100 nM in 9/15 multiple myeloma cell lines, decreases methylation of PABP1 (IC50?=38 nM) and SmB (IC50=18 nM); displays dose-dependent inhibition of CARM1 substrate methylation in vivo, and induces growth inhibition of human multiple myeloma tumor xenografts in mice.
-
体外实验EZM 2302 binds to CARM1 and is a selective inhibitor of CARM1 activity (IC50=6?nM) with broad selectivity against other histone methyltransferases. Treatment of MM cell lines with EZM 2302 leads to inhibition of PABP1 and SMB methylation and cell stasis with IC50 values in the nanomolar range (9, 31 nM, respectively). EZM 2302 inhibits the in vitro proliferation of multiple hematopoietic cell lines, with day 14 IC50 values of less than 100?nM in 9 of 15 cell lines.
-
体内实验EZM 2302 is stable in human hepatocytes (CL<3?mL/min/kg), and moderately binds to human, mouse and rat plasma proteins with a mean fraction unbound of 0.66, 0.46 and 0.74, respectively. In mouse and rat, the plasma clearance (CL) is 43 and 91?mL/min/kg, respectively. EZM 2302 shows dose-dependent exposure and tumor growth inhibition (TGI) after 21 days in the RPMI-8226 xenograft model. Tumors in all EZM 2302 dose groups measured on day 21 show significant decreases in tumor growth compared to vehicle.
-
同义词GSK 3359088 | GSK3359088 | EZM2302
-
通路Chromatin/Epigenetic
-
靶点HMTase
-
受体HMTase
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1628830-21-6
-
分子量585.102
-
分子式C29H37ClN6O5
-
纯度>98% (HPLC)
-
溶解度100 mM in DMSO
-
SMILESO=C(N(CC1)CCC21CN(C3=NC(C4=CC(OC[C@H](O)CNC)=CC=C4Cl)=NC(C5=C(C)ON=C5C)=C3C)C2)OC
-
化学全称methyl (R)-2-(2-(2-chloro-5-(2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Drew AE, et al. Sci Rep. 2017 Dec 21;7(1):17993.
2. Greenblatt SM, et al. Cancer Cell. 2018 Jun 11;33(6):1111-1127.e5.